Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered ...

Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. In this multicenter trial with a 2-by-2 ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

COLCHICINE has been shown to inhibit deoxyribonuclease and de-phosphorylation and de-amination of deoxyribonucleotides 1. The beneficial effect of colchicine in gout is possibly due to the effect ...

WASHINGTON, DC—The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients ...

Colchicine-binding site inhibitors present good selectivity and minor acquired multidrug resistance and toxicity effects compared to antitubulin drugs, such as docetaxel, paclitaxel, vincristine or ...

WASHINGTON, DC – OCTOBER 29, 2024 – The largest trial to examine the impact of colchicine in acute myocardial infarction (MI) found that both acute and long-term colchicine use did not reduce ...